A Randomized, Single-blind, Placebo-controlled, 4-Week Treatment Study of the Safety and Biologic Activity of Escalating Multiple Oral Doses of FG-4592 in Subjects With Chronic Kidney Disease Not Requiring Dialysis
Phase of Trial: Phase II
Latest Information Update: 12 Aug 2015
Price : $35 *
At a glance
- Drugs Roxadustat (Primary)
- Indications Anaemia
- Focus Adverse reactions
- Sponsors FibroGen
- 12 Aug 2015 Results were published in a FibroGen media release.
- 03 Aug 2015 Results published in the Nephrology Dialysis Transplantation.
- 18 Sep 2014 New trial record